COMBINATION THERAPIES FOR MELANOMA COMPRISING ADMINISTERING COBIMETINIB AND VEMURAFENIB

摘要

The present invention relates a method for treating BRAF^V600 mutation-positive unresectable or metastatic melanoma comprising administering to a patient a first composition comprising cobimetinib or a pharmaceutically acceptable salt thereof, and a second composition comprising vemurafenib or a pharmaceutically acceptable salt thereof, wherein cobimetinib is administered at a dose of 60 mg, on days 1-21 of a 28 day cycle, and vemurafenib is administered at a dose of 960 mg twice daily, each day of the 28 day cycle.